Flisiak R, Prokopowicz D
Department of Infectious Diseases, Medical Academy of Białystok, Poland.
Clin Chem Lab Med. 2000 Nov;38(11):1129-31. doi: 10.1515/CCLM.2000.170.
The aim of the study was to evaluate the possible association between plasma concentrations of transforming growth factor-beta1 (TGF-beta1) and the degree of hepatic dysfunction in patients with chronic liver diseases. TGF-beta1 was measured with an enzyme immunoassay in plasma from 21 patients with chronic active hepatitis and 40 patients with liver cirrhosis. Normal values were obtained from a group of 13 healthy volunteers. Results were analysed with respect to aetiology and the degree of liver insufficiency as evaluated by the Child-Pugh classification. The mean plasma concentration of TGF-beta1 in patients (36.9+/-2.8 ng/ml) was twice that found in normal volunteers (18.3+/-1.6 ng/ml). The highest values were observed in patients with alcoholic liver cirrhosis (44.4+/-4.7 ng/ml). Plasma TGF-beta1 showed a statistically significant positive correlation with the degree of liver insufficiency. These results indicate the possible use of plasma TGF-beta1 measurement as a good marker of liver function impairment. Further observation of patients involved in this study may help to evaluate its possible prognostic value in chronic liver diseases.
本研究旨在评估慢性肝病患者血浆转化生长因子-β1（TGF-β1）浓度与肝功能障碍程度之间的可能关联。采用酶免疫分析法检测了21例慢性活动性肝炎患者和40例肝硬化患者血浆中的TGF-β1。正常数值取自13名健康志愿者。根据病因以及通过Child-Pugh分类法评估的肝功能不全程度对结果进行了分析。患者血浆TGF-β1的平均浓度（36.9±2.8 ng/ml）是正常志愿者（18.3±1.6 ng/ml）的两倍。酒精性肝硬化患者的值最高（44.4±4.7 ng/ml）。血浆TGF-β1与肝功能不全程度呈统计学显著正相关。这些结果表明，血浆TGF-β1检测有可能作为肝功能损害的良好标志物。对本研究中患者的进一步观察可能有助于评估其在慢性肝病中的潜在预后价值。
